1-4 of 4
Melissa A. Law
Close
Sort by
Journal Articles

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA -positive chronic eosinophilic leukemia: implications for optimal dosing

Clinical Trials & Observations
Amy D. Klion, Jamie Robyn, Irina Maric, Weiming Fu, Laura Schmid, Steven Lemery, Pierre Noel, Melissa A. Law, Marilyn Hartsell, Cheryl Talar-Williams, Michael P. Fay, Cynthia E. Dunbar, Thomas B. Nutman
Journal: Blood
Blood (2007) 110 (10): 3552–3556.
https://doi.org/10.1182/blood-2007-07-100164
Published: 2007
Journal Articles

Familial eosinophilia: a benign disorder?

Clinical Trials & Observations
Amy D. Klion, Melissa A. Law, William Riemenschneider, Mary Lou McMaster, Margaret R. Brown, McDonald Horne, Barbara Karp, Michael Robinson, Vandana Sachdev, Eben Tucker, Maria Turner, Thomas B. Nutman
Journal: Blood
Blood (2004) 103 (11): 4050–4055.
https://doi.org/10.1182/blood-2003-11-3850
Published: 2004
Journal Articles

Safety and efficacy of the monoclonal anti–interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome

Clinical Trials & Observations Brief Report
Amy D. Klion, Melissa A. Law, Pierre Noel, Yae-Jean Kim, Thomas P. Haverty, Thomas B. Nutman
Journal: Blood
Blood (2004) 103 (8): 2939–2941.
https://doi.org/10.1182/blood-2003-10-3620
Published: 2004
Journal Articles

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

Clinical Trials & Observations
Amy D. Klion, Pierre Noel, Cem Akin, Melissa A. Law, D. Gary Gilliland, Jan Cools, Dean D. Metcalfe, Thomas B. Nutman
Journal: Blood
Blood (2003) 101 (12): 4660–4666.
https://doi.org/10.1182/blood-2003-01-0006
Published: 2003